Abstract
The study concerns 17 eyes which, following vitrectomy, were given an injection of 25 μg of tissue plasminogen activator (tPA). Of these 17 cases, ten showed a severe fibrin formation in the anterior chamber, 3 cases showed vitreous hemorrhage (one of them with hyphema), 2 had fibrin formation and cellular proliferation, while in one case tPA was injected at the end of the vitrectomy because of perisilicone proliferation and in one case because of fibrin depositions on the intraocular lens.
The tPA was injected into the anterior chamber (10 eyes) or into the vitreous cavity (7 eyes). The follow-up period ranged from 4 to 15 months (mean period 91/2 months). Fibrinolysis was noted in the 10 cases with fibrin formation in the anterior chamber. Fibrin dissolution was achieved within 3–4 hours. None of these cases presented a recurrence throughout the follow-up period. Positive results were observed also in the case with perisilicone proliferation. On the contrary in 3 cases with postvitrectomy hemorrhage the hemorrhage persisted unchanged. Also in 2 cases with fibrin formation and cellular proliferation on the anterior and posterior surface of the iris the tPA injection proved ineffective. Both cases developed traction retinal detachment (TRD) due to anterior proliferative vitreoretinopathy (PVR). In the case with fibrin depositions on the intraocular lens the situation remained unchanged. Any complications observed in our case proved to be mild and transitory.
Similar content being viewed by others
References
Collen D, Topol EJ, Tiefenbrunn AJ, et al. Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomised, placebo-controlled trial. Circulation 1984; 70: 1012–7.
Dabbs CK, Aaberg TM, Aguilar HE, Sternberg P, Meredith TA, Ward AR. Complications of tissue plasminogen activator therapy after vitrectomy for diabetes. Am J Ophthalmol 1990; 110: 354–60.
Eiman MJ, Quinian P, Fine SL, et al. Thrombolytic therapy for central retinal vein occlusion. Invest Ophthalmol Vis Sci 1988; 29 (suppl): 68.
Folk J, Hershey J, Rivers M. Lack of effectiveness of tissue plasminogen activator 20 or more days after vitrectomy. Arch Ophthalmol 1991; 109: 614.
Howard GR, Vukich J, Fishella RG, Farber MD, Goldberg MF. Intraocular tissue plasminogen activator in rabbit model of traumatic hyphema. Arch Ophthalmol 1991; 109: 272–4.
Irvine WD, Johnson MW, Hernandez E, Olsen K. Retinal toxicity of human tissue plasminogen activator in vitrectomized rabbit eyes. Arch Ophthalmol 1991; 109: 718–22.
Jaffe GJ, Abrams GW, Williams GA, Han DP. Tissue plasminogen activator for postvitrectomy fibrin formation. Ophthalmol 1990; 97: 184–9.
Jaffe GJ, Green GDJ, Abrams GW. Stability of recombinant tissue plasminogen activator (letter). Am J Ophthalmol 1989; 108: 90–1.
Jaffe GJ, Lewis H, Han DP, Williams GA, Abrams GW. Treatment of postvitrectomy fibrin pupillary block with tissue plasminogen activator. Am J Ophthalmol 1989; 108: 170–5.
Johnson MW, Olsen KR, Hernandez E, Irvine WD, Johnson RN. Retinal toxicity of recombinant tissue plasminogen activator in the rabbit. Arch Ophthalmol 1990; 108: 259–63.
Johnson RN, Olsen KR, Hernandez E. Intravitreal tissue plasminogen activator treatment of experimental vitreous hemorrhage. Arch Ophthalmol 1989; 107: 891–4.
Lambrou FH, Snyder RW, Williams GA. The use of tissue plasminogen activator in experimental hyphema. Arch Ophthalmol 1987; 105: 995–7.
Lewis H, Resnick SC, Flannery JG, Straatsma BR. Tissue plasminogen activator treatment of experimental subretinal hemorrhage. Am J Ophthalmol 1991; 111: 197–204.
Lim J, Fishella R, Tessler H, Gagliano D, Chaques-Alupez V, Mohler M. Intraocular penetration of topical tissue plasminogen activator. Arch Ophthalmol 1991; 109: 714–7.
Oncel M, Peyman GA, Khoobehi B. Tissue plasminogen activator in the treatment of experimental retinal vein occlusion. Retina 1989; 9: 1–7.
Ortiz JR, Walker SO, McManus PE, Martinez LA, Brown RH, Jaffe GJ. Filtering bleb thrombolysis with tissue plasminogen activator. Am J Ophthalmol 1988; 106: 624–5 (letter to the Journal).
Sternberg P, Aguilar HE, Drews G, Aaberg TM. The effect of tissue plasminogen activator on retinal bleeding. Arch Ophthalmol 1990; 108: 720–2.
Vine AK, Maguire PT, Martonyi C, Kincaid MC. Recombinant tissue plasminogen activator to lyse experimentally induced retinal arterial thrombi. Am J Ophthalmol 1988; 105: 266.
Williams DF, Han DP, Abrams GM. Rebleeding in experimental traumatic hyphema treated with intraocular tissue plasminogen activator. Arch Ophthalmol 1990; 108: 264–6.
Williams GA, Lambrou FH, Jaffe GJ, et al. Treatment of postvitrectomy fibrin formation with intraocular tissue plasminogen activator. Arch Ophthalmol 1988; 106: 1055–8.
Williams DF, Borer J, Braunwald E, et al. Intravenous recombinant tissue-type plasminogen activator in patients with acute myocardial infarction: a report from the NHLBI thrombolysis in myocardial infarction trial. Circulation 1986; 73: 338–46.
Williams DF, Bennett SR, Abrams GW, Han DP, Mieler WF, Jaffe GJ, Williams GA. Low-dose intraocular tissue plasminogen activator for treatment of postvitrectomy fibrin formation. Am J Ophthalmol 1990; 109: 606–7.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Koutsandrea, C., Apostolopoulos, M. & Theodossiadis, P. The use of tissue plasminogen activator in postvitrectomy cases. Int Ophthalmol 17, 95–100 (1993). https://doi.org/10.1007/BF00942782
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00942782